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Advanced imaging techniques may enable early
diagnosis and monitoring of therapy in various
rheumatic diseases. To prevent irreversible tissue
damage, inflammatory rheumatic disease must be
diagnosed and treated in pre-clinical stages, requiring
highly sensitive detection techniques. Positron emission
tomography (PET) provides highly sensitive, quantitative
imaging at a molecular level, revealing the important
pathophysiological processes underlying inflammation.
This review provides an overview of the current utility
of 18 F-fluorodeoxyglucose (FDG)-PET/computed
tomography (CT) in patients with active rheumatic
diseases such as rheumatoid arthritis, spondyloarthritis,
polymyalgia rheumatica, adult-onset Still’s disease,
relapsing polychondritis, immunoglobulin G4-related
disease, large-vessel vasculitis, Wegener’s granulomatosis,
polymyositis, and dermatomyositis. We also discuss the
role of FDG-PET/CT in the diagnosis and monitoring of
these diseases.(HIF1α) mediates cancer cell metabolism and shifts cancer
cells into oxygen conservation mode, aerobic glycolysis, soIntroduction
Timely diagnosis and early effective treatment can im-
prove the outcome of various inflammatory rheumatic
diseases [1]. To enable early diagnosis and individualized
therapeutic protocols, sensitive monitoring tools such as
advanced imaging techniques are needed. Promising re-
sults have already been obtained by using anatomical
imaging modalities, such as magnetic resonance imaging
(MRI) and ultrasound (US), which allow highly sensitive
detection of synovitis and bone marrow edema in in-
flammatory arthropathies and vascular thickening in sys-
temic vasculitis [2-4]. Each technique, however, has
drawbacks and limitations; MRI usually produces im-
ages within a limited field of view, and US is limited by* Correspondence: hiroyuki_yjp2005@yahoo.co.jp
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unless otherwise stated.variability and labor intensity. In addition, in the presence
of inflammation, both techniques can visualize indirect in-
flammatory signs such as increased tissue water content
and hyperperfusion.
Because diagnosis and assessment of disease activity at
subclinical stages are increasingly important, nuclear
imaging techniques are becoming more widely used. In
this review, the potential role of 18 F-fluorodeoxyglucose
positron emission tomography/computed tomography
(FDG-PET/CT) in the diagnosis and monitoring of inflam-
matory rheumatic diseases is discussed.Part I. The usefulness of PET/CT imaging in the
assessment of the severity of the disease
FDG-PET for inflammatory diseases
Increased ‘aerobic glycolysis’ in cancer cells, originally
described by Otto Warburg, provides a growth advan-
tage to tumor cells. With the imbalance in the growth of
capillaries and cancer cells, cancer cells become hypoxic.
The transcription factor hypoxia-inducible factor 1α
that the reduced oxygen consumption saves cancer cells
from anoxic death; that is, HIF1α regulates the expression
of glucose transporters, hexokinase, and other factors in
cancer cells [5].
FDG is used to trace glucose metabolism. Many cancer
cells showed elevated expression of glucose transporters
and hexokinase. Most cancer cells are FDG-avid, and a
fusion imaging technique combining PET/CT, which
provides information on both anatomy and glucose me-
tabolism, has improved the diagnostic accuracy and is
now widely used in oncology.
FDG uptake is not limited to cancer cells; uptake may
also occur in various inflammatory cells. Elevated FDG
uptake by activated macrophages and by newly formed
granulation tissue was demonstrated by Kubota and
colleagues [6,7] in the early 1990s. The uptake of FDG by
cancer cells is postulated to involve the same mechanism
as in inflammatory cells. Cramer and colleagues [8]tral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
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cell (granulocytes and monocytes/macrophages) infiltra-
tion and activation an in vivo inflammation model. More
recently, Matsui and colleagues [9] reported FDG uptake
in the area in which inflammatory cell infiltration and
synovial cell hyperplasia were visible in an arthritis
model. Based on in vitro experiments, Matsui and col-
leagues suggested that the cell types responsible for FDG
uptake are activated macrophages and proliferating fibro-
blasts in the presence of cytokine stimulation and under
hypoxic circumstances within a joint. The FDG uptake
by inflammatory tissue, such as arthritis lesions, seems to
reflect the inflammatory activity accurately. Such studies
have strongly encouraged the clinical application of
FDG-PET/CT for rheumatic diseases.
Rheumatoid arthritis
Typical FDG-PET/CT images of rheumatoid arthritis
(RA) are shown in Figure 1. In 1995, the first FDG-PET
studies in patients with active RA revealed increased FDG
uptake in clinically inflamed wrist joints. Furthermore,
standardized uptake values (SUVs) for FDG were corre-
lated with clinical indicators such as tenderness and swell-
ing [10]; these findings were confirmed in other studiesFigure 1 Typical 18 F-fluorodeoxyglucose-positron emission tomograp
rheumatoid arthritis (RA). (A) Maximum intensity projection and (B, C) ax
polyarthritis. She was diagnosed with RA based on the presence of symmet
inflammatory reaction (C-reactive protein, 12.72 mg/dL) and magnetic resona
showed (A) symmetrical arthritis and remarkable circular FDG uptake due to s[11,12]. FDG SUV data in arthritis are also correlated with
disease activity score 28 (DAS28) and simple disease activ-
ity index values. The number of FDG-positive joints is also
strongly correlated with their cumulative SUV and disease
duration [11]. However, Goerres and colleagues [13] found
that simple visual semi-quantitative scoring (from 0 to 4)
based on FDG joint uptake [12] also reflected clinical evi-
dence of inflammation in joints. This approach eliminates
the need to quantify tracer uptake but lacks objectivity. On
the other hand, the semi-quantitative analysis using SUVs
has better objectivity. Okamura and colleagues [14] found
that the SUVs for 12 joints correlated with tender joint
count (TJC) and that the SUVs for eight joints correlated
with DAS28, DAS28-C-reactive protein (CRP), and TJC in
patients with RA, suggesting a close relationship between
SUVs for large joints and disease activity.
Beckers and colleagues [11] reported sensitivities of up
to 90% in a study evaluating 356 joints of 21 patients
with established RA by using FDG-PET. In this study,
visually identified FDG positivity was clearly associated,
according to odds ratios, with both joint swelling and
tenderness. Regarding specificity, FDG-PET allows excel-
lent differentiation between inflamed and healthy joints,
both among patients with RA and between patients andhy/computed tomography (FDG-PET/CT) findings in a patient with
ial FDG-PET/CT findings of RA in an 86-year-old woman presenting with
rical polyarthritis that continued for more than 19 weeks with a severe
nce imaging findings that showed synovitis and tendinitis. FDG-PET/CT
ynovitis around the (B) shoulders and (C) hips.
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at all [11,15]. However, despite a greater number of
FDG-positive joints in RA than in osteoarthritis patients,
absolute values for tracer uptake do not differ between
these two conditions [16]. Nonetheless, whole-body PET
may aid in differentiation between RA and other inflam-
matory joint diseases, as differences in bio-distribution
patterns have allowed distinction between some forms of
arthritis associated with connective tissue disease [17].
Recently, several studies have indicated that sub-
clinical disease is present during clinical remission
and may be related to progression of joint damage
[18]. Owing to its high sensitivity and ability to scan
multiple joints in one session, PET may allow detec-
tion of such subclinical disease activity. Whole-body
PET scanning in 18 patients with RA, four of whom
were in remission, showed significant differences be-
tween those with active arthritis and those in clinical
remission [12]. FDG uptake by large joints, total vis-
ual PET scores for involved joints, SUVmax, and the
mean number of joints per patient with high FDG
uptake were all significantly lower for patients in
clinical remission. In all patients in remission, how-
ever, increased FDG uptake was still observed in one
or more joints, suggesting subclinical disease activity.
Besides its ability to detect and monitor subclinical
disease, PET may have prognostic power. Recently,
FDG changes in inflamed hand joints after 2 weeks
of infliximab treatment were correlated with DAS28
joint scores at 14 to 22 weeks of treatment [19]. In
contrast, erythrocyte sedimentation rate (ESR), CRP,
and DAS28 scores had no such predictive value after
2 weeks of therapy.
Comparison of semiquantitative PET data with US
data and clinical findings [11] revealed a significant lin-
ear correlation between SUVs and synovial thickness, as
measured by US, for nearly all joints. This relationship
was stronger for larger joints, as these are more accur-
ately evaluated by semiquantitative scoring [20]. More-
over, for anatomical reasons, some small joints in the
hand cannot easily be evaluated in three dimensions by
US [21]. The first study simultaneously investigating
PET, MRI, and US in patients with RA showed that en-
hanced FDG uptake was associated with positive find-
ings obtained by the other two imaging techniques [16].
In addition, the study revealed correlations among SUVs
from PET, relative contrast enhancement from MRI, and
synovial thickness from US.
Over the last few years, hybrid PET-CT and PET-MRI
have become available. Combining PET with CT has
helped place pathophysiologic PET information in its
anatomic context [22]. Thus, hybrid imaging should
allow more precise localization of PET signals, and
PET-MRI should limit radiation exposure [23].Spondyloarthritis
Typical FDG-PET/CT images of spondyloarthritis (SpA)
are shown in Figure 2 [24]. SpA includes ankylosing
spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis,
enteropathic arthritis, and undifferentiated SpA [25]. SpA
often involves enthesitis, sacroiliitis, and inflammatory
spondylitis [26].
Taniguchi and colleagues [27] evaluated the accuracy
of FDG-PET/CT in detecting enthesitis in patients with
SpA. PET/CT scans of the shoulder, hip, and knee joints
revealed that FDG accumulates at the entheses in SpA
and in the synovium in patients with RA. SUVmax was
significantly higher at the enthesis of the lumbar spinous
process, pubic symphysis, and ischial tuberosity in pa-
tients with SpA than in patients with RA. Lumbar spin-
ous processes and ischial tuberosities appeared more
frequently via PET/CT than MRI in patients with SpA.
The authors concluded that PET/CT represents an alter-
native modality to identifying enthesitis and will likely
contribute to the early diagnosis of SpA.
Strobel and colleagues [28] evaluated the performance
of FDG-PET/CT for the diagnosis of sacroiliac joint (SIJ)
arthritis in patients with active AS by using patients with
mechanical low back pain (MLBP) as a control. The
mean ratios of FDG uptake in the SIJ to that in the sacrum
were 1.66 in patients with AS and 1.12 in patients with
MLBP. With plain radiography as the gold standard and
using a sacroiliac joint to sacrum (SIJ/S) ratio of 1.3 as the
threshold, the sensitivity and specificity of FDG-PET/CT
for arthritis were 80% and 77%, respectively. On a per-SIJ
basis, the greatest sensitivity (94%) was found in grade 3
sacroiliitis. These results suggest that quantitative FDG-
PET/CT may be useful to diagnose sacroiliitis in active AS,
providing an alternative to conventional bone scintigraphy
in times of molybdenum shortage.
We used FDG-PET/CT to compare SUVs in various
joints in 53 patients with SpA, polymyalgia rheumatica
(PMR), and RA [24]. In patients with SpA, SUVmax in
the SIJ was greater than in patients with PMR or RA.
No significant difference in vertebral scores was ob-
served among groups. PET/CT findings thus can distin-
guish SpA from RA and PMR and are useful for the
early diagnosis of sacroiliitis.
Vijayant and colleagues [29] evaluated the potential of
FDG-PET in the early assessment of treatment response
in various rheumatic diseases, including 11 patients with
newly diagnosed SpA and one patient with PsA. In the
SpA group, FDG uptake in the affected joint was hetero-
geneous, low-grade, and non-symmetrical, with intense
tendon and muscular uptake in symptomatic joints. In
contrast, FDG uptake in the patient with PsA was in-
tense in the joints and soft tissue. If larger studies cor-
roborate these findings, FDG-PET could be useful to
distinguish RA from SpA.
Figure 2 Typical 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) and magnetic resonance
imaging (MRI) findings in patients with spondyloarthritis (SpA), enthesitis of the ischial tuberosity, and sacroiliitis. (A) Whole-body FDG-PET/CT
in a patient with SpA reveals FDG accumulation in the ischial tuberosity (A1). MRI (fat-suppressed, T1-weighted imaging) reveals enhancement in the
areas surrounding the ischial tuberosity, consistent with enthesitis (A2-3). (B) FDG accumulation suggestive of sacroiliitis in the sacroiliac joint in patients 1
and 2 on FDG-PET/CT (B1). MRI (fat-suppressed, T1-weighted imaging) identifies contrast enhancement in patient 2 (B2).
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Typical FDG-PET/CT images of PMR are shown in
Figure 3 [30]. PMR is an inflammatory rheumatic disease
characterized by aches and morning stiffness in the shoul-
ders, hip girdle, and neck in patients over 50 years of age.
PMR is diagnosed by the exclusion of other disorders caus-
ing similar complaints and by its rapid response to low-
dose corticosteroid therapy [31,32]. Although its pathology
is unknown, synovitis and bursitis are common features of
this disease. MRI and US frequently reveal inflammation of
the tenosynovial sheaths of the hands or feet [33-35].
Moosig and colleagues [36] quantified FDG accumula-
tion in large vessels in 13 untreated patients with PMR by
PET and compared these data with serological markers of
inflammation. By visual evaluation, FDG uptake by the
aorta or its major branches increased in 12 of 13 patients.
In active PMR, the mean region of interest (ROI) index
for all vascular regions exceeded that of controls by 70%.
In active PMR, FDG uptake was significantly correlated
with CRP, ESR, and platelet counts. The observed FDG ac-
cumulation in the aorta and its branches and the strong
correlation between tracer uptake and markers of inflam-
mation suggest that large-vessel arteritis is characteristic
of active PMR.
Blockmans and colleagues [37] investigated whether
FDG deposition in various vascular lesions and largejoints of patients with isolated PMR predicts relapse. All
patients underwent an FDG-PET scan before steroid
treatment and at 3 and 6 months; seven vascular areas
were scored, and a total vascular score (TVS), ranging
from 0 to 21, was calculated. At diagnosis, vascular FDG
uptake was noted in 31% of patients, predominantly at
the subclavian arteries. FDG uptake in the shoulders was
noted in 94% of patients, in the hips in 89%, and in the
spinous process of the vertebrae in 51%. FDG uptake in-
tensity was not correlated with the risk of relapse in ei-
ther the large vessels or large joints.
Whereas Blockmans and colleagues [37] analyzed
FDG-PET changes in patients with PMR, we analyzed
the precise distribution of lesions via PET/CT and
evaluated differences in FDG accumulation between
PMR and similar diseases. In patients with PMR, FDG
uptake was increased in ischial tuberosities, greater
trochanters, and lumbar spinous processes [30]. Posi-
tive results at two or more of these sites were highly
sensitive (85.7%) and specific (88.2%) for the diagnosis
of PMR, and shoulder or hip joint involvement was
not disease-specific. High FDG accumulation was found
in the aortas and subclavian arteries of two PMR pa-
tients in whom FDG uptake did not identify temporal
arteritis or scanty synovium and perisynovium. PET/
CT images of the 12 PMR patients without apparent
Figure 3 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) images at diagnosis and after
steroid treatment in a patient with isolated polymyalgia rheumatica (PMR). FDG uptake in the (A) shoulders, (B) spinous processes of the
lower lumbar vertebrae, (C) iliopectineal bursitis, and (D) ischial tuberosity is normalized after therapy (A-D, right panels).
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or both.
We also used FDG-PET/CT to compare SUVs in various
joints in 53 patients with SpA, PMR, and RA [24]. In pa-
tients with PMR, the SUVmax for ischial tuberosities was
significantly higher than in patients with SpA or RA, and
those in the greater trochanter and spinous processes were
also significantly higher than in patients with RA.
Furthermore, we compared PET/CT findings in a large
number of PMR cases with those in patients with elderly-
onset RA (EORA), which is extremely difficult to distin-
guish from PMR. We observed no significant difference in
FDG uptake in the shoulders or hips. However, specific up-
take patterns were observed in each group: circular and
linear uptake patterns around the humeral head in EORA
and focal and nonlinear uptake patterns in PMR. More-
over, focal uptake at the front of the hip joint, indicating
iliopectineal bursitis, tended to be limited to the PMR
group. The sensitivity and specificity for PMR diagnosis
were very high at 92.6% and 90.0%, respectively, when at
least three of the five items, including findings characteris-
tic of shoulder and iliopectineal bursitis, FDG uptake in is-
chial tuberosities and spinal spinous processes, and lack of
FDG uptake in the wrists, were satisfied. FDG-PET/CT
may be useful for the detection of PMR lesions, which are
difficult to identify by using other methods.Adult-onset Still’s disease
Typical FDG-PET/CT images of adult-onset Still’s dis-
ease (AOSD) are shown in Figure 4 [38]. We first evalu-
ated FDG-PET/CT for diagnosis and disease evaluation
of AOSD by investigating FDG uptake for characteristic
findings in seven patients with AOSD and reviewing the
literature on seven previous reports of PET/CT in pa-
tients with AOSD [38]. FDG accumulation was positive
mainly in the bone marrow (100%), spleen (90.9%), lymph
nodes (80.0%), and joints (75.0%). In addition, FDG uptake
was positive in the pericardium, pleura, salivary glands,
eyelids, muscle, and major blood vessels. Follow-up PET/
CT showed diminished FDG accumulation, as measured
by SUVmax, in the bone marrow, spleen, and lymph nodes.
The only correlation with laboratory data was between
lactate dehydrogenase and spleen SUV. In conclusion,
FDG-PET/CT is useful for long-term assessment of AOSD
activity in individual patients. However, PET/CT findings
alone are not sufficient to make a differential diagnosis of
AOSD versus malignant lymphoma.
Relapsing polychondritis
Typical FDG PET/CT images of relapsing polychondritis
(RPC) are shown in Figure 5 [39]. RPC is relatively rare,
and early diagnosis is difficult. We first investigated the
utility of FDG-PET/CT for the diagnosis and evaluation
Figure 4 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) images at diagnosis and after
steroid and tocilizumab treatment in a patient with adult-onset Still’s disease (AOSD). (A1, B1, and C1) Marked FDG accumulation was
observed in the bone marrow, spleen, and multiple lymph nodes at diagnosis. (A2, B2, and C2) After treatment, FDG uptake decreased in these
sites - bone marrow, from SUVmax = 4.02 (A1) to 2.50 (A2); spleen, from SUVmax = 6.05 (A1 and C1) to 4.38 (A2 and C2) - as well as in multiple
lymph nodes, including in the axilla, mediastinum, hilar region of the lung, hilar region of the liver, and para-aortic region (B1/C1→ B2/C2). SUV,
standardized uptake value.
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PET/CT in our hospital and eight cases in the literature
[39]. Typical FDG accumulation was noted in tracheo-
bronchial trees, costal cartilage, joints, larynx, nasal cavity/
paranasal sinuses, auricles, lymph nodes, and the aorta. In
one patient, PET revealed nasal chondritis despite an ab-
sence of nasal changes upon physical examination. Of five
patients with costochondritis, four remained asymptom-
atic. Of nine patients with airway FDG accumulation, eight
developed respiratory symptoms and all had CT abnormal-
ities. In the remaining patient, airway FDG accumulation
was evident despite the absence of airway symptoms and a
lack of abnormalities in the respiratory function test or CT.
PET also revealed bronchial chondritis in asymptomatic
patients. In the five patients examined by PET post-
treatment, FDG accumulation diminished as symptoms
improved and inflammation decreased. We conclude that
FDG-PET/CT is a potentially powerful tool for the early
diagnosis of RPC, especially in patients with affected or-
gans that are difficult to biopsy. This modality also facili-
tates the evaluation of extent of disease and disease activity
during treatment.
IgG4-related disease
IgG4-related disease (IgG4-RD) is a systemic disorder
associated with lesions characterized by mass formationin multiple specific organs. This disorder comprises
Mikulicz’s disease, autoimmune pancreatitis (AIP), hypo-
physitis, Riedel thyroiditis, interstitial pneumonitis, intersti-
tial nephritis, lymphadenopathy, retroperitoneal fibrosis,
and inflammatory pseudotumour [40]. The combination of
such lesions on FDG-PET/CT may strongly suggest or
support the diagnosis of IgG-4RD.
Shigekawa and colleagues [41] noted that the FDG-
PET pattern at baseline, including extra-abdominal lymph
nodes or salivary glands (or both) and the involvement of
the eyes and biliary ducts, can be useful for discriminating
between AIP and pancreatic cancer. Ozaki and colleagues
[42] also found that FDG uptake by hilar lymph nodes was
significantly more frequent in AIP than in pancreatic can-
cer and reported that uptake by the lacrimal gland, salivary
gland, biliary duct, retroperitoneal space, and prostate was
seen only in AIP. They reported that a longitudinal pat-
tern, heterogeneous accumulation, and multiple localiza-
tions in the pancreas indicated AIP rather than pancreatic
cancer [42].
Ebbo and colleagues [43] evaluated FDG-PET/CT for
disease staging and treatment evaluation in 46 FDG-
PET/CT images from 21 patients with IgG4-RD. At diag-
nosis or relapse, all patients presented abnormal FDG
uptake at sites typically affected by IgG4-RD. In most
cases, FDG-PET/CT was more sensitive than conventional
Figure 5 Comparison of pre- and post-treatment 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography
(FDG-PET/CT) images in a patient with relapsing polychondritis (RPC). (A) Maximum intensity projection and (B-D) axial FDG-PET/CT
findings of RPC in a 74-year-old female patient presenting with nasal symptoms. The patient was positive for type II anti-collagen antibody, and
nasal cartilage biopsy was consistent with RPC. FDG accumulation (SUVmax = 13.03) is well defined from the infrahilar region of the left inferior lobe
to the pulmonary hilus (A1 and B1, arrow) and conspicuous in the nasal cavity (SUVmax = 9.50) (C1 and D1, arrow). Neither bronchial wall thickening
nor bronchial stricture is apparent. Post-treatment images show a complete lack of accumulation (A2-D2). SUV, standardized uptake value.
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teries, salivary glands, and lymph nodes. In a few cases,
FDG-PET/CT failed to identify small or contiguous lesions
in the brain or kidneys.
In addition, we evaluated the utility of FDG-PET/CT
in eight patients with IgG4-RD [44]. Although nearly all
patients were negative for CRP, various organs took up
significant amounts of FDG. In conclusion, FDG accu-
mulation in organs characteristically affected by IgG4-
RD allows diagnosis without evidence of an associated
inflammatory reaction.
Large-vessel vasculitis
Typical FDG-PET/CT images of large-vessel vasculitis
(LVV) are shown in Figure 6 [45]. From a systematic re-
view on FDG-PET/CT in patients with LVV, Treglia and
colleagues [46] drew several conclusions. First, FDG-
PET/CT appears to be useful in early diagnosis and in
the assessment of disease activity and extent. Second,
the correlation between FDG-PET findings and sero-
logical inflammatory markers as well as the usefulness
of FDG-PET/CT in evaluating treatment response re-
quire further investigation. Additionally, FDG-PET/CT
appears to be superior to conventional imaging methods,
such as US or MRI, in the diagnosis of LVV but not in
predicting relapse or evaluating vascular complications.Lastly, PET analysis and diagnostic criteria should be
standardized to allow reproducible, directly comparable
results.
We also studied the usefulness of FDG-PET/CT and
contrast-enhanced CT in early diagnosis and treatment
follow-up of patients with LVV presenting as elderly-
onset inflammation of unknown origin (IUO) [45]. For
quantitative comparison, we evaluated SUVmax and PET
scores of the aortic wall, as well as aortic wall thickness
(W) and its ratio with respect to aortic radius (W/R) by
contrast-enhanced CT, and compared pre-treatment and
post-treatment values. Of 124 patients who were hospi-
talized because of advanced age and IUO, 10.5% had
LVV, and more than half had non-specific symptoms.
Compared with control subjects, patients with LVV
showed significantly higher aortic wall SUVmax, higher
PET scores as revealed by FDG-PET/CT, and increased
aortic wall thicknesses as revealed by contrast-enhanced
CT. In conclusion, LVV is an important cause of IUO
with non-specific symptoms in older patients. Imaging
examination comprising contrast-enhanced CT and FDG-
PET/CT is useful for early diagnosis and early treatment
evaluation of LVV, as it detects amelioration of aortic wall
thickening.
Notably, FDG-PET/CT may be negative for old lesions
even if the arterial stricture is severe. Lesions in which
Figure 6 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) images at diagnosis and after
steroid treatment in a patient with large-vessel vasculitis. (A) FDG-PET/CT at diagnosis identifies aortitis in the thoracic and abdominal aorta
and arteritis bilaterally in the subclavian and axillary vessels as strong uptake in the walls of the aorta and arteries. (B) Update decreased markedly
during steroid treatment.
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be appropriate for evaluation by FDG-PET; in such
cases, morphological imaging such as MRI or contrast-
enhanced CT may be used. Again, LVV should be diag-
nosed in the early phase with FDG-PET/CT to prevent
stricture formation.
Wegener’s granulomatosis
Wegener’s granulomatosis (WG), namely granulomatosis
with polyangiitis, is a relatively rare disease characterized
by granulomatous necrotizing vasculitis. In the first
evaluation of FDG-PET/CT imaging for the diagnosis
and monitoring of WG [47], we retrospectively analyzed
13 FDG-PET/CT images obtained from eight patients.
WG lesions of the upper respiratory tract and lung were
more clearly detected by FDG-PET/CT fusion imaging
than by non-enhanced CT alone. In addition, FDG-PET/
CT can be combined with other imaging methods to in-
form selection of biopsy sites. Ozmen and colleagues
[48] also reported PET/CT to be useful for detecting ac-
tive lesions (except in the kidneys) and for identifying bi-
opsy sites in patients with WG. FDG-PET/CT is more
useful than traditional imaging studies, such as CT, for
differentiating between active lesions due to WG and re-
sidual foci of inflammation. It is also useful for detecting
active lesions in unexpected sites such as large vessels
and the spleen. In conclusion, FDG PET/CT is a feasible
modality for evaluating lesion activity in WG.Polymyositis and dermatomyositis
Owada and colleagues [49] examined whether FDG-PET
can detect myositis or extramuscular lesions in patients
with polymyositis (PM) and dermatomyositis (DM) and
observed increased FDG uptake in muscle in 33% of
patients. The sensitivity of FDG-PET to detect myositis
was lower than that of electromyography, MRI, and muscle
biopsy, and patients with and without increased FDG up-
take in muscle did not differ clinically, although those with
FDG muscle uptake had a tendency toward extended myo-
sitis with endomysial cell infiltration. In contrast, FDG-
PET did detect neoplasms in patients with associated
malignancy, which accounted for 38.9% of patients with
interstitial lung disease. Thus, FDG-PET imaging appears
to have limited usefulness for the evaluation of myositis in
patients with PM and DM because of its low sensitivity.
On the other hand, Tanaka and colleagues [50] also
conducted a retrospective study to determine whether
FDG-PET/CT discriminates PM and DM from non-
muscular diseases and whether FDG uptake in proximal
muscles reflects severity of muscular inflammation. Mean
proximal muscle SUVs were significantly greater in pa-
tients with PM and DM than in controls and were corre-
lated with mean proximal manual muscle test scores and
serum creatine kinase and aldolase levels. Furthermore,
SUVs in proximal muscles from which biopsy speci-
mens were obtained were significantly correlated with
histological grade for inflammatory cell infiltration. These
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of PM and DM when inflammation in proximal muscles is
also quantitatively assessed by other means. These results
also indicate that local FDG uptake reflects inflammatory
activity in proximal muscle and can help guide biopsy site
selection.
Part II. The usefulness of PET/CT imaging in the
therapy response assessment
Rheumatoid arthritis
FDG-PET images do detect reductions in metabolism
and treatment-related changes in the volume of pannus
that are not detectable with conventional imaging [10].
In 2006, Beckers and colleagues [51] used FDG-PET to
image joints before and after anti-TNF therapy and
found that PET positivity was correlated with higher SUVs.
In contrast, FDG-PET revealed no significant metabolic
changes following acupuncture treatment of affected knees
in six patients with chronic RA [52].
Recently, Okamura and colleagues [14] investigated the
correlations between SUVmax in 12 large joints and clinical
parameters in 22 patients with RA before and after treat-
ment with biologics. The results showed positive correla-
tions of ΔSUV with ΔDAS28, ΔDAS28-CRP, and ΔTJC in
large joints before and after treatment, suggesting the use-
fulness of PET in evaluating treatment responses [14].
A number of studies have examined the ability of PET
to accurately indicate treatment outcomes compared
with MRI. Before and during treatment with non-steroidal
anti-inflammatory drugs, prednisone, or methotrexate,
changes in joint uptake of FDG, as revealed by PET, were
strongly correlated with synovial volume upon MRI in pa-
tients with RA [10,53].
The first study simultaneously investigating PET, MRI,
and US in patients with RA showed that changes in SUVs
in RA-affected knees after initiation of anti-TNF therapy
were also correlated with changes in MRI parameters and
serum CRP and metalloproteinase-3 levels but not with
changes in synovial thickness as measured via US [51].
Spondyloarthritis
Vijayant and colleagues [29] evaluated the potential of
FDG-PET in the early assessment of treatment response
in various rheumatic diseases, including one patient with
PsA. Post-treatment scans were performed in one pa-
tient with PsA. There was a significant fall in SUVmax
correlating to the clinical improvement in the patient.
FDG-PET also appears to be a sensitive tool in the early
assessment of treatment response, especially when using
quantitative information.
Polymyalgia rheumatica
Typical FDG-PET/CT images of PMR are shown in
Figure 3 [24]. In our case, FDG accumulation tended todecrease in the areas of bursitis and iliopsoas bursitis of
the shoulder, the spinous process, and the ischial tuber-
osity after treatment, suggesting the usefulness of FDG-
PET/CT for evaluating treatment effects.
Moosig and colleagues [36] quantified FDG accumula-
tion in large vessels in 13 untreated patients with PMR
by PET. Among the eight patients who underwent
follow-up PET, the mean ROI index for all vascular re-
gions declined substantially.
Blockmans and colleagues [37] investigated whether
FDG deposition in various vascular lesions and large
joints of patients with PMR predicts relapse. All patients
underwent an FDG-PET scan before steroid treatment
and at 3 and 6 months. Repetitive PET scintigraphy after
3 months of steroid treatment resulted in a decrease of
TVS and a lower intensity of FDG uptake in shoulders,
hips, and spinous process. At 3 months, all but two pa-
tients had significantly decreased laboratory parameters
of inflammation. This decrease of FDG uptake probably
reflects a lower disease activity, but sedimentation rate
and CRP levels, which are much cheaper to perform, re-
flect the same. So this does not justify a repeat PET scan.
Adult-onset Still’s disease
Typical FDG-PET/CT images of AOSD are shown in
Figure 4 [38]. In our case, FDG accumulation tended to
decrease in the bone marrow, spleen, and lymph nodes
after treatment, suggesting the usefulness of FDG-PET/
CT for evaluating treatment effects.
Relapsing polychondritis
Typical FDG PET/CT images of RPC are shown in
Figure 5 [39]. In our case, FDG accumulation tended to
decrease in the bronchial wall, hilar lymph nodes, and
nasal cavity after treatment, suggesting the usefulness of
FDG PET/CT for evaluating treatment effects.
IgG4-related disease
Ebbo and colleagues [43] evaluated FDG-PET/CT for
disease staging and treatment evaluation in 46 FDG-
PET/CT images from 21 patients with IgG4-RD. Evalu-
ation before and after treatment showed that FDG-PET/
CT results were generally correlated with treatment
response and disease activity. This retrospective study
shows that FDG-PET/CT imaging is useful for staging
IgG4-RD and assessing treatment response. In addition,
residual organic pathology may be present even if serum
IgG4 levels have been decreased by steroid therapy. In
such cases, PET images are considered to be useful for
evaluating the IgG4-RD disease activity.
Large-vessel vasculitis
Typical FDG-PET/CT images of LVV are shown in
Figure 6 [45]. In our case, FDG accumulation tended
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eral subclavian and axillary arteries, suggesting the useful-
ness of FDG-PET/CT for evaluating treatment effects.
From a systematic review on FDG-PET/CT in patients
with LVV, Treglia and colleagues [46] concluded that
FDG-PET/CT appears to be superior to conventional
imaging methods in assessing response to immunosup-
pressive treatment.
We also studied the usefulness of FDG-PET/CT and
contrast-enhanced CT in early diagnosis and treatment
follow-up of patients with LVV [45]. PET scores and
contrast-enhanced CT revealed significant reductions in
aortic wall thickness following treatment. In conclusion,
imaging examination comprising contrast-enhanced CT
and FDG-PET/CT is useful for early treatment evalu-
ation of LVV, as it detects amelioration of aortic wall
thickening.
Wegener’s granulomatosis
We retrospectively analyzed 13 FDG-PET/CT images
obtained from eight patients with WG. All active lesions
showed decreased FDG uptake after treatment [47].
Ozmen and colleagues [48] also showed significantly de-
creased FDG uptake after complete remission of WG in
their PET/CT study. FDG-PET/CT is more useful than
traditional imaging studies, such as CT, for differentiat-
ing between active lesions and residual loci of inflamma-
tion in patients with WG. Furthermore, PET/CT allows
earlier evaluation of treatment responses as well as earlier
detection of recurrent disease than CT. In conclusion,
FDG PET/CT is a feasible modality for evaluating thera-
peutic efficacy in WG.
The potential applications of immuno-PET
The development of non-invasive imaging techniques
using monoclonal antibodies (mAbs) is a quickly evolv-
ing field. Immuno-PET uses positron-emitting isotopes
to track the localization of mAbs with excellent image
quality. Procedures for labeling mAbs with 89Zr or 124I
by using good manufacturing procedures have been
established, and therefore these radiopharmaceuticals
are being investigated for clinical use. Immuno-PET is
expected to become an option as a non-invasive diagnos-
tic tool providing ‘comprehensive immunohistochemical
staining in vivo’ [54]. Therefore, immuno-PET has enor-
mous potential for diagnosing rheumatic disease and
evaluating its activity in the presence of disease-specific
mAbs.
Summary of review
It is sometimes difficult to distinguish between RA and
other rheumatic diseases such as SpA and PMR, which
lack specific serum markers; PET may be useful for dif-
ferentiating among these conditions. Moreover, no specificserum markers exist for AOSD, making its differentiation
from other rheumatic diseases occasionally difficult. How-
ever, the finding of FDG accumulation in the bone marrow,
spleen, lymph nodes, and joints in this condition is useful.
It should be acknowledged, however, that differentiation of
AOSD from malignant lymphomas is sometimes difficult.
As for RPC, it is possible to identify asymptomatic chon-
dritis by using PET and readily identify the distribution of
the lesions. With respect to IgG4-RD, the diagnostic yield
can be increased by recognizing the characteristic distribu-
tion of the lesions in this disease by using PET combined
with the absence of a significant inflammatory response. In
addition, LVV can be cited in the differential diagnosis as a
cause of IUO in older patients who present with non-
specific symptoms only; PET is useful for early diagnosis of
this condition, and early therapeutic intervention may pre-
vent stenotic lesions. With regard to WG (granulomatosis
with polyangiitis (GPA)), PET is useful for the evaluation
of active lesions, therapeutic monitoring, and identification
of biopsy sites. As for inflammatory myopathy, whereas
one report suggests the limited usefulness of PET because
of its low sensitivity, another report suggests that PET pro-
vides useful information for determining the appropriate
biopsy sites.
Conclusions
FDG-PET/CT can provide information on active inflam-
matory lesions. It is a very sensitive but non-specific im-
aging modality. The distribution patterns of inflammatory
foci sometimes suggest specific disease. In general, if FDG-
PET/CT imaging is used appropriately, it may provide very
helpful information for accurate diagnosis. In addition,
FDG-PET/CT is very sensitive for monitoring disease ac-
tivity. It could be applied to the prediction of therapeutic
response, but further studies are required. FDG-PET/CT is
a promising imaging modality for rheumatic diseases.
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